MSOS stock and what to expect next with MSOS stock

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) – Biotech Investments

Biophytis / Key word(s): Miscellaneous Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) 08-Apr-2024 / 23:00 CET/CEST Biophytis launches OBA phase

April 10, 2024

ESC 2024: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam – Pharmaceutical Technology

Amvuttra showed a significant reduction in mortality and cardiovascular events for ATTR amyloidosis with cardiomyopathy patients in the Helios B trial. Credit: Tada Images via

August 30, 2024

How a cash-prize system that phases out patents may lower drug prices

Two months ago, Sen. Bernie Sanders (I-Vt.) moved a step closer to an idea he has championed for some time — awarding prizes, instead of

September 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.